Leukemia News

In this video, Akriti Jain, MD, discusses the results of a study on treatment patterns and outcomes for patients with acute myeloid Leukemia , which showed that outcomes improved over the past decade.

SAN DIEGO — Infections are the main driver of mortality not related to disease relapse among individuals who received chimeric antigen receptor T cells, results of a meta-analysis presented at ASH Annual Meeting and Exhibition showed.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab was well tolerated and showed promising efficacy in patients with relapsed or refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Early treatment with lenalidomide resulted in a prolonged time to subsequent therapy in patients with high-risk chronic lymphocytic leukemia, according to extended follow-up data presented at ASH Annual Meeting and Exposition.

Combination ibrutinib and venetoclax for first-line treatment yielded a 5-year PFS of 90.1% and 5-year OS of 95.6% in 120 patients with chronic lymphocytic leukemia, according to long-term follow-up data presented at ASH Annual Meeting.

Higher mutational burden was linked to shorter time to first treatment in untreated patients with chronic lymphocytic leukemia independently of other genomic events, according to an abstract presented at ASH Annual Meeting and Exposition.

Time-limited dual B-cell receptor inhibitor therapy with acalabrutinib, umbralisib and ublituximab showed potential in treatment-naive and relapsed/refractory chronic lymphocytic leukemia, according to data presented at ASH Annual Meeting.

Real-world data showed that Bruton tyrosine kinase inhibitors were a reasonable therapeutic option for patients with chronic lymphocytic leukemia and severe renal impairment, including for older adults and those on dialysis.

In this video, Eunice Wang, MD, discusses data presented at the ASH Annual Meeting and Exposition that validates menin inhibitors as a new class of targeted therapy for AML.

In this video, Eunice Wang, MD, discusses the use of venetoclax azacitidine as a standard of care therapy for the treatment of acute myeloid leukemia.